从国际技术首创到国内、国际标准引领，从生物材料到生命材料，锦波生物凭借先发优势、原始创新能 力等构筑起业内"牌照壁垒"。面对行业竞争愈发激烈的情况，公司将完善产品矩阵和渠道，致力于建设 国际一流的科技创新型生物材料企业。 核心产品不断突破 在公司展厅内，锦波生物副总经理陆晨阳举起红蓝相间的模型，展示了重组Ⅲ型人源化胶原蛋白的原子 三螺旋结构。公司2018年通过生物合成的方式，在国际上首次发现、解析了Ⅲ型胶原蛋白核心功能区原 子结构，即呈现164.88°柔性弯曲的三螺旋结构。 "正是依托'164.88°根技术'，锦波生物不断进行技术升级，推出新产品。"陆晨阳介绍，公司的"全人源 化胶原蛋白新材料"是我国首个有自主知识产权的原创型新型生物材料。公司还首次实现了广谱抗HPV 生物蛋白、广谱抗新冠病毒多肽药物的产业化及终端产品开发。 锦波生物被称为A股"重组人源化胶原蛋白第一股"。自2021年公司第一张重组人源化胶原蛋白三类医疗 器械注册证获批至今，锦波生物独揽三张重组人源化胶原蛋白三类医疗器械注册证，实现了冻干纤维、 溶液、凝胶全剂型覆盖。 今年9月，锦波生物"重组Ⅲ型人源化胶原蛋白冻干纤维"正式获得国家药监局药品 ...

Core Insights - The 2025 BIO-Europe conference was held in Vienna, Austria, from November 3 to 5, showcasing the advancements in biopharmaceuticals and precision medicine from Shanxi Province [3][4] - The Shanxi delegation, organized by the China Council for the Promotion of International Trade Shanxi Committee, included key pharmaceutical companies that aimed to enhance international collaboration and showcase their innovations [3][4] Company Highlights - Shanxi Shuangyan Pharmaceutical Co., Ltd. promoted its high-end active pharmaceutical ingredients and formulations, certified by FDA and EDQM, with exports to over 50 countries [4] - Shanxi Zhendong Pharmaceutical Co., Ltd. showcased its achievements in the modernization of traditional Chinese medicine and functional health foods [4] - Shanxi Naan Biotechnology Co., Ltd. introduced its self-developed Bio-Lattix technology platform and innovative drug pipelines, including ADCs and RDCs [4] - Taiyuan Huarui Qiyuan Technology Co., Ltd. presented the world's first commercial standing CT and diagnostic reagent culture device, attracting attention from medical and investment institutions [4] - Shanxi Jinbo Biopharmaceutical Co., Ltd. displayed its proprietary human-derived collagen new materials and broad-spectrum antiviral bioproducts, highlighting its leading green manufacturing technology [4] - Shanxi Yellow River Traditional Chinese Medicine Co., Ltd. showcased its 300-year-old brand "Yishengtang," emphasizing the integration of traditional Chinese medicine culture with modern research [4] Industry Collaboration - The Shanxi delegation engaged in in-depth discussions with various European biopharmaceutical companies, research institutions, and investment funds during the conference [4] - The delegation leader, Wang Xiu, emphasized the importance of this event in promoting Shanxi pharmaceutical companies to expand into international markets and enhance the global influence of the "Shanxi brand" [4]